Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer.

Adjuvant chemotherapy has played a major role in the treatment of hormone receptor-positive breast cancer for many years. To better determine which patient subsets need adjuvant chemotherapy, various gene expression analyses have been developed, but cost-effective tools to identify such patients remain elusive. In the present report, we retrospectively investigated immunohistochemical expression and subcellular localization of MUC1 in primary tumors and examined their relationship to tumor malignancy, chemotherapy effect and patient outcomes. We retrospectively examined three patient cohorts with hormone receptor-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: 51 patients who underwent 21-gene expression analysis (multi-gene assay-cohort), 96 patients who received neoadjuvant chemotherapy (neoadjuvant chemotherapy-cohort), and 609 patients whose tumor tissue was used in tissue-microarrays (tissue-microarray-cohort). The immunohistochemical staining pattern of the anti-MUC1 monoclonal antibody, Ma695, was examined in cancer tissues, and subcellular localization was determined as apical, cytoplasmic or negative. In the multi-gene assay-cohort, tumors with apical patterns had the lowest recurrence scores, reflecting lower tumor malignancy, and were significantly lower than MUC1-negative tumors (P = 0.038). In the neoadjuvant chemotherapy-cohort, there was no correlation between MUC1 staining patterns and effects of chemotherapy. Finally, in the tissue-microarray-cohort, we found that patients with apical MUC1 staining patterns had significantly longer disease-free-survival and overall survival than other patterns (P = 0.020 and 0.039, respectively). Our data suggest that an apical MUC1 staining pattern indicates luminal A-likeness. Assessment of the subcellular localization of MUC1 glycoprotein may be useful for identifying patients who can avoid adjuvant chemotherapy.

A Case of Adenomyoepithelioma With a Pleomorphic Adenoma-Like Component of the Male Breast.

Adenomyoepithelioma (AME) of the male breast is a rare tumor characterized by biphasic proliferation of gland epithelial cells and myoepithelial cells. Though pleomorphic adenoma (PA) is also known to be an epithelial-myoepithelial tumor in the breast, and these tumors are considered to exist on the same spectrum by some authors, to the best of our knowledge, there have been no reports of a clear transition from AME to PA in the male breast. Therefore, the case of an 85-year-old man with AME with PA-like components is presented.

Preoperative optical coherence tomography visualization of epiretinal membranes enhances surgical strategies.

PURPOSE: The aim of this study was to evaluate the usefulness of preoperative optical coherence tomography (OCT) findings in patients with macular epiretinal membrane (ERM) for the planning of surgical strategy. PATIENTS AND METHODS: One hundred twenty-three eyes of 121 patients (49 men, 72 women; mean age, 66 years) with an idiopathic ERM were enrolled. All patients underwent an ophthalmic examination including indirect ophthalmoscopy and OCT (Cirrus HD-OCT 4000 and/or 5000). OCT images obtained using model 4000 were transferred to the model 5000 system for vitreoretinal interface (VRI) analysis. The retinal thickness in each area, occurrence rate, and locations of the edges and partial detachments of the ERMs were evaluated using OCT. RESULTS: OCT detected identifiable edges in 61 (50%) eyes and partial detachments in 116 (94%) of the 123 eyes. The edges and partial detachments were seen more frequently in the inferior macula. VRI analysis also detected the edges and partial detachments. Excluding the central area, the superior quadrant was the thickest in patients with an ERM. CONCLUSION: Preoperatively acquired OCT images are useful for planning surgical strategies and performing the surgeries smoothly.